يعرض 1 - 20 نتائج من 1,562 نتيجة بحث عن '"A. A. Shatokhin"', وقت الاستعلام: 0.57s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Report
  4. 4
    Report
  5. 5
    Academic Journal
  6. 6
    Report
  7. 7
    Report
  8. 8
    Academic Journal
  9. 9
    Report
  10. 10
    Academic Journal

    المصدر: Омский научный вестник: Серия "Общество. История. Современность", Vol 8, Iss 3, Pp 116-123 (2023)

    وصف الملف: electronic resource

    Relation: https://www.omgtu.ru/general_information/media_omgtu/journal_of_omsk_research_journal/files/arhiv/2023/%D0%A2.8,%20%E2%84%963%20(%D0%9E%D0%98%D0%A1)/116-123%20%D0%9A%D1%83%D1%80%D0%B0%D0%B5%D0%B2%20%D0%90.%20%D0%9D.,%20%D0%9C%D0%BE%D1%80%D0%BE%D0%B7%D0%BE%D0%B2%D0%B0%20%D0%98.%20%D0%93.,%20%D0%93%D1%80%D1%83%D0%BD%D0%B8%D0%BD%D0%B0%20%D0%90.%20%D0%90.,%20%D0%A1%D1%83%D1%80%D0%B0%D0%B9%20%D0%9D.%20%D0%9C.,%20%D0%A8%D0%B0%D1%82%D0%BE%D1%85%D0%B8%D0%BD%20%D0%9C.%20%D0%92..pdf; https://doaj.org/toc/2542-0488; https://doaj.org/toc/2541-7983

  11. 11
    Report
  12. 12
    Academic Journal

    المصدر: Омский научный вестник: Серия "Общество. История. Современность", Vol 9, Iss 3, Pp 124-134 (2024)

    Relation: https://www.omgtu.ru/general_information/media_omgtu/journal_of_omsk_research_journal/files/arhiv/2024/%D0%A2.9,%20%E2%84%96%203%20(%D0%9E%D0%98%D0%A1)/124-134%20%D0%90%D0%BD%D1%82%D1%80%D0%BE%D0%BF%D0%BE%D0%B2%D0%B0%20%D0%A2.%20%D0%93.,%20%D0%A8%D0%B0%D1%82%D0%BE%D1%85%D0%B8%D0%BD%20%D0%9C.%20%D0%92.,%20%D0%A1%D1%83%D1%80%D0%B0%D0%B9%20%D0%9D.%20%D0%9C.pdf; https://doaj.org/toc/2542-0488; https://doaj.org/toc/2541-7983; https://doaj.org/article/05d70cde44424ffdb20569bdbee99e73

  13. 13
    Academic Journal
  14. 14
  15. 15
    Academic Journal

    المساهمون: The work was financially supported by the Russian Science Foundation under grant No. 23-15-00310 “Personalized pharmacotherapy of patients with benign prostatic hyperplasia based on the use of molecular biomarkers of ADME-processes”., Работа выполнена при финансовой поддержке Российского научного фонда по гранту № 23-15-00310 «Персонализированная фармакотерапия пациентов с доброкачественной гиперплазией предстательной железы на основе использования молекулярных биомаркеров ADME-процессов».

    المصدر: Pharmacy & Pharmacology; Том 1, № 1 (2024); 32-48 ; Фармация и фармакология; Том 1, № 1 (2024); 32-48 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2024-1-1

    وصف الملف: application/pdf

    Relation: https://www.pharmpharm.ru/jour/article/view/1449/1024; https://www.pharmpharm.ru/jour/article/view/1449/1023; Wei J.T., Calhoun E., Jacobsen S.J. Urologic diseases in America project: benign prostatic hyperplasia // J Urol. – 2005. – Vol. 173, No. 4. – P. 1256–1261. DOI:10.1097/01.ju.0000155709.37840.fe; McVary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., Foster H.E. Jr., Gonzalez C.M., Kaplan S.A., Penson D.F., Ulchaker J.C., Wei J.T. Update on AUA guideline on the management of benign prostatic hyperplasia // J Urol. – 2011. – Vol. 185, No. 5. – P. 1793–1803. DOI:10.1016/j.juro.2011.01.074; Michel M.C., Kenny B., Schwinn D.A. Classification of alpha 1-adrenoceptor subtypes // Naunyn Schmiedebergs Arch Pharmacol. – 1995. – Vol. 352, No. 1. – P. 1–10. DOI:10.1007/BF00169183; Roehrborn C.G. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. – 2009. – Vol. 11, Suppl 1. – P. S1–S8.; Knox C., Wilson M., Klinger C.M., Franklin M., Oler E., Wilson A., Pon A., Cox J., Chin N.E.L., Strawbridge S.A., Garcia-Patino M., Kruger R., Sivakumaran A., Sanford S., Doshi R., Khetarpal N., Fatokun O., Doucet D., Zubkowski A., Rayat D.Y., Jackson H., Harford K., Anjum A., Zakir M., Wang F., Tian S., Lee B., Liigand J., Peters H., Wang R.Q.R., Nguyen T., So D., Sharp M., da Silva R., Gabriel C., Scantlebury J., Jasinski M., Ackerman D., Jewison T., Sajed T., Gautam V., Wishart D.S. DrugBank 6.0: the Drug-Bank Knowledgebase for 2024 // Nucleic Acids Research. – 2024. – Vol. 52, No. D1. – P. D1265–D1275. DOI:10.1093/nar/gkad976; Domanski T.L., Finta C., Halpert J.R., Zaphiropoulos P.G. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 // Mol Pharmacol. – 2001. – Vol. 59, No. 2. – P. 386–392. DOI:10.1124/mol.59.2.386; Huang W., Lin Y.S., McConn D.J. 2nd, Calamia J.C., Totah R.A., Isoherranen N., Glodowski M., Thummel K.E. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism // Drug Metab Dispos. – 2004. – Vol. 32, No. 12. – P. 1434–1445. DOI:10.1124/dmd.104.001313; Kivistö K.T., Bookjans G., Fromm M.F., Griese E.U., Münzel P., Kroemer H.K. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue // Br J Clin Pharmacol. – 1996. – Vol. 42, No. 3. – P. 387–389. DOI:10.1046/j.1365-2125.1996.42615.x; Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians // J Pharmacol Exp Ther. – 1994. – Vol. 270, No. 1. – P. 414–423.; Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism // Adv Drug Deliv Rev. – 2002. – Vol. 54, No. 10. – P. 1271–1294. DOI:10.1016/s0169-409x(02)00066-2; Ozdemir V., Kalow W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., Kashuba A.D. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method // Pharmacogenetics. – 2000. – Vol. 10, No. 5. – P. 373–388. DOI:10.1097/00008571-200007000-00001; Mulder T.A.M., van Eerden R.A.G., de With M., Elens L., Hesselink D.A., Matic M., Bins S., Mathijssen R.H.J., van Schaik R.H.N. CYP3A4*22 Genotyping in Clinical Practice: Ready for Implementation? // Front Genet. – 2021. – Vol. 12:711943. DOI:10.3389/fgene.2021.711943; Pratt V.M., Cavallari L.H., Fulmer M.L., Gaedigk A., Hachad H., Ji Y., Kalman L.V., Ly R.C., Moyer A.M., Scott S.A., van Schaik R.H.N., Whirl-Carrillo M., Weck K.E. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase // J Mol Diagn. – 2023. – Vol. 25, No. 9. – P. 619–629. DOI:10.1016/j.jmoldx.2023.06.008; Saiz-Rodríguez M., Almenara S., Navares-Gómez M., Ochoa D., Román M., Zubiaur P., Koller D., Santos M., Mejía G., Borobia A.M., Rodríguez-Antona C, Abad-Santos F. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates // Biomedicines. – 2020. – Vol. 8, No. 4. – P. 94. DOI:10.3390/biomedicines8040094; Werk A.N., Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014. – Vol. 96, No. 3. – P. 340–348. DOI:10.1038/clpt.2014.129; Van Schaik R.H., van der Heiden I.P., van den Anker J.N., Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002. – Vol. 48, No. 10. – P. 1668–1671. DOI:10.1093/clinchem/48.10.1668; Bains R.K., Kovacevic M., Plaster C.A., Tarekegn A., Bekele E., Bradman N.N., Thomas M.G. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa // BMC Genet. – 2013. – Vol. 14. – Art. ID: 34. DOI:10.1186/1471-2156-14-34; Whirl-Carrillo M., Huddart R., Gong L., Sangkuhl K., Thorn C.F., Whaley R., Klein T.E. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine // Clin Pharmacol Ther. – 2021. – Vol. 110, No. 3. – P. 563–572. DOI:10.1002/cpt.2350; Birdwell K.A., Decker B., Barbarino J.M., Peterson J.F., Stein C.M., Sadee W., Wang D., Vinks A.A., He Y., Swen J.J., Leeder J.S., van Schaik R., Thummel K.E., Klein T.E., Caudle K.E., MacPhee I.A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing // Clin Pharmacol Ther. – 2015. – Vol. 98, No. 1. – P. 19–24. DOI:10.1002/cpt.113; Смирнов В.В., Савченко А.Ю., Раменская Г.В. Разработка и валидация методики количественного определения эндогенного кортизола и 6-β-гидроксикортизола в моче с целью определения активности изофермента CYP 3A4 // Биомедицина. – 2010. – № 4. – С. 56–60.; Kim K.A., Park I.B., Park J.Y. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans // Eur J Clin Pharmacol. – 2018. – Vol. 74, No. 10. – P. 1281–1289. DOI:10.1007/s00228-018-2501-x; Villapalos-García G., Zubiaur P., Navares-Gómez M., Saiz-Rodríguez M., Mejía-Abril G., Martín-Vílchez S., Román M., Ochoa D., Abad-Santos F. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin // Front Pharmacol. – 2021. – Vol. 12. – Art. ID: 718281. DOI:10.3389/fphar.2021.718281; Choi C.I., Bae J.W., Jang C.G., Lee S.Y. Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype // J Clin Pharmacol. – 2012. – Vol. 52, No. 12. – P. 1934–1938. DOI:10.1177/0091270011432168; Cho C.K., Kang P., Park H.J., Lee Y.J., Bae J.W., Jang C.G., Lee S.Y. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele // Arch Pharm Res. – 2021. – Vol. 44, No. 11. – P. 1037–1049. DOI:10.1007/s12272-021-01357-z; Застрожин М.С., Гришина Е.А., Скрябин В.Ю., Галактионова Т.Е., Барна И.В., Антоненко А.П., Вдовина М.Н., Пахомов С.Р., Савченко Л.Д., Брюн Е.А., Сычев Д.А. Влияние полиморфизма гена ABCB1 на эффективность и безопасность бромдигидрохлорфенилбензодиазепина у пациентов с тревожными расстройствами, коморбидными с алкогольной зависимостью // Наркология. – 2019. – Т. 18, № 6. – С. 39–50. DOI:10.25557/1682-8313.2019.06. 39-50; Застрожин М.С., Панов А.С., Гришина Е.А., Смирнов В.В., Рыжикова К.А., Шипицын В.В., Иванов А.В., Скрябин В.Ю., Сорокин А.С., Савченко Л.Д., Брюн Е.А., Сычев Д.А. Влияние активности CYP3A на эффективность и безопасность карбамазепина у пациентов с аффективными расстройствами, коморбидными с алкогольной зависимостью // Наркология. – 2019. – Т. 18, № 2. – С. 60–68. DOI:10.25557/1682-8313.2019.02.60-68; Kamimura H., Oishi S., Matsushima H., Watanabe T., Higuchi S., Hall M., Wood S.G., Chasseaud L.F. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes // Xenobiotica. – 1998. – Vol. 28, No. 10. – P. 909–922. DOI:10.1080/004982598238985; https://www.pharmpharm.ru/jour/article/view/1449

  16. 16
  17. 17
    Report
  18. 18
    Report
  19. 19
    Report
  20. 20
    Report